


Amendments to the Claims

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1. (Original) Crystalline non-solvated 1-(4-(2-piperidinyloxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride having an X-ray diffraction pattern which comprises the following peaks: 15.2 ± 0.1 , 17.6 ± 0.1 , 18.6 ± 0.1 and $24.1 \pm 0.1^\circ$ in 2θ ; when the pattern is obtained from a copper radiation source ($\text{CuK}\alpha$, $\lambda = 1.54056 \text{ \AA}$).
2. (Original) The salt of Claim 2 wherein said X-ray diffraction pattern further comprises the following peaks: 16.9 ± 0.1 , 19.2 ± 0.1 , 21.3 ± 0.1 and $21.6 \pm 0.1^\circ$ in 2θ .
3. (Amended) A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of ~~either claim 1 or~~ claim 1 or 2.
4. (Amended) A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of ~~either claim 1 or 2~~.
5. (Cancelled)
6. (New) A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of claim 2.
7. (New) A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of claim 2.

Respectfully submitted,



Gilbert T. Voy
Attorney for Applicants
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

July 9, 2005